Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP14 | P50281 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942807 | 1.00 | MMP2 (0.45) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL167977 | 0.88 | MMP2 (0.46) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL6680100 | 0.86 | MMP2 (0.45) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL60869 | 0.81 | L3MBTL1 (0.43) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL219767 | 0.80 | MMP1 (0.37) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL29406060 | 0.80 | MMP1 (0.37) | MMP2MMP1MMP3KMT2AELANE | |
| SCHEMBL6566817 | 0.80 | L3MBTL1 (0.44) | KMT2AELANEMAPTALDH1A1LMNA | |
| SCHEMBL3191723 | 0.79 | KMT2A (0.46) | KMT2AELANEMAPTPKMHTT | |
| SCHEMBL5466190 | 0.78 | BCL9 (0.56) | KMT2AMAPTPKMALDH1A1HTT | |
| SCHEMBL10636410 | 0.77 | ELANE (0.39) | MMP2MMP1MMP3KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647947-B2 | Detergent composition | NOVOZYMES A/S (DK) | 2020-05-12 | — | — | US | claimed |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-05-19 | — | — | US | disclosed |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4739760-A1 | WASHING METHOD FOR REMOVING PROTEINACEOUS STAINS | Novozymes A/S (DK) | 2026-05-13 | — | — | EP | disclosed |
| EP-3607038-B1 | CLEANING COMPOSITIONS AND USES THEREOF | NOVOZYMES AS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-3708660-B1 | POLYPEPTIDES | NOVOZYMES AS (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-12606810-B2 | Subtilase variants and compositions comprising same | NOVOZYMES A/S (DK) | 2026-04-21 | — | — | US | disclosed |
| EP-3704220-B1 | METHODS FOR CLEANING MEDICAL DEVICES | NOVOZYMES AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4717756-A2 | LIPASE VARIANTS AND DETERGENT COMPOSITIONS | Novozymes A/S (DK) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078359-A1 | POLYPEPTIDES | NOVOZYMES A/S (DK) | 2026-03-19 | — | — | US | disclosed |
| EP-0313146-A2 | Detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0299575-A1 | Detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0297673-A2 | Detergent/softening compositions containing hectorite clays | THE PROCTER & GAMBLE COMPANY (US) | 1989-01-04 | — | — | EP | disclosed |
| US-4758378-A | Softening detergent compositions containing amide softening agent | THE PROCTER & GAMBLE COMPANY (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0274142-A2 | Detergent composition containing a polyamide softening agent | THE PROCTER & GAMBLE COMPANY (US) | 1988-07-13 | — | — | EP | disclosed |
| EP-0269169-A2 | Detergent compositions containing cellulase | THE PROCTER & GAMBLE COMPANY (US) | 1988-06-01 | — | — | EP | disclosed |
| EP-0269168-A2 | Softening detergent compositions containing cellulase | THE PROCTER & GAMBLE COMPANY (US) | 1988-06-01 | — | — | EP | disclosed |
| EP-0242918-A1 | Softening and bleaching detergent compositions containing amide softening agent | THE PROCTER & GAMBLE COMPANY (US) | 1987-10-28 | — | — | EP | disclosed |
| EP-0242919-A1 | Softening detergent compositions containing amide softening agent | THE PROCTER & GAMBLE COMPANY (US) | 1987-10-28 | — | — | EP | disclosed |
| US-4588532-A | Preparation of para-acyloxybenzene sulfonates | RHONE-POULENC CHIMIE DE BASE (FR) | 1986-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | LIPE, LPL, PNLIP | MMP2 262/4885MMP1 237/4885MMP3 455/4885 |
| US-20260078359-A1 | POLYPEPTIDES | IDUA, IDE, AGL | MMP2 147/4885MMP1 182/4885MMP3 937/4885 |
| US-12606810-B2 | Subtilase variants and compositions comprising same | PRSS1, CTRL, TMPRSS11D | MMP2 158/4885MMP1 250/4885MMP3 94/4885 |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | RNASE1, PEPD, DPP9 | MMP2 107/4885MMP1 270/4885MMP3 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.